European Regulators Begin Formal Review of Lyme Disease Vaccine Candidate

The European Medicines Agency (EMA) has validated the marketing authorization application for Pfizer and Valneva's Lyme disease vaccine candidate, PF-07307405. This validation initiates the formal assessment process by the EMA, supported by Phase III clinical trial data showing over 70% efficacy. This marks a significant step towards potential approval and availability of a vaccine for Lyme disease in Europe.